Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6

Hepatology

Volumn 52, Issue 5, 2010, Pages 1573-1580

  Lam, Khoa D ^a,b   Trinh, Huy N ^a,c   Do, Son T ^d   Nguyen, Thuan T ^e   Garcia, Ruel T ^a,c   Nguyen, Tuan ^f   Phan, Quang Q ^g   Nguyen, Huy A ^c   Nguyen, Khanh K ^c   Nguyen, Long H ^a,h   Nguyen, Mindie H ⁱ  

^a Pacific Health Foundation   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c San Jose Gastroenterology   (United States)

^d Digestive Health Associates of Texas   (United States)

^e Division of Gastroenterology and Hepatology   (United States)

^f Division of Gastroenterology and Hepatology   (United States)

^g Gastroenterology and Hepatology   (United States)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; AGE DISTRIBUTION; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; FEMALE; FEVER; GASTROENTEROLOGY; GENOTYPE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HYPERTHYROIDISM; INJECTION SITE IRRITATION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAPID VIROLOGIC RESPONSE; RASH; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; VIRUS LOAD; VOMITING;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CALIFORNIA; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; SAFETY; TEXAS; VIRAL LOAD; YOUNG ADULT;

EID: 78049512501     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23889     Document Type: Article

References (30)

1. World Health Organization. Hepatitis C. Fact Sheet No. 164. Geneva, Switzerland: WHO; 1999.
2. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556- 562.
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
5. Kanistanon D, Neelamek M, Dharakul T, Songsivilai S. Genotypic distribution of hepatitis C virus in different regions of Thailand. J Clin Microbiol 1997; 35: 1772-1776.
6. Leung N, Chu C, Tam JS. Viral hepatitis C in Hong Kong. Intervirology 2006; 49: 23-27.
7. Lu L, Nakano T, He Y, Fu Y, Hagedorn CH, Robertson BH. Hepatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants. J Med Virol 2005; 75: 538-549.
8. Lwin AA, Shinji T, Khin M, Win N, Obika M, Okada S, Koide N. Hepatitis C virus genotype distribution in Myanmar: predominance of genotype 6 and existence of new genotype 6 subtype. Hepatol Res 2007; 37: 337-345.
9. Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005; 3: S97-S101.
10. Wong DA, Tong LK, Lim W. High prevalence of hepatitis C virus genotype 6 among certain risk groups in Hong Kong. Eur J Epidemiol 1998; 14: 421-426.
11. Zhou Y, Wang X, Mao Q, Fan Y, Zhu Y, Zhang X, et al. Changes in modes of hepatitis C infection acquisition and genotypes in southwest China. J Clin Virol 2009; 46: 230-233.
12. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. HEPATOLOGY 2005; 42: 962-973.
13. Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. HEPATOLOGY 2002; 36: 1259-1265.
14. Fung J, Lai CL, Hung I, Young J, Cheng C, Wong D, et al. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis 2008; 198: 808-812.
15. Hui CK, Yuen MF, Sablon E, Chan AO, Wong BC, Lai CL. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. J Infect Dis 2003; 187: 1071-1074.
16. Nguyen MH, Trinh HN, Garcia R, Nguyen G, Lam KD, Keeffe EB. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol 2008; 103: 1131-1135.
17. Cheng JT, Hsien C, Sun HE, Tong MJ. The emerging importance of chronic hepatitis C infection in Asian Americans. Am J Gastroenterol 2006; 101: 2737-2743.
18. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293.
19. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007; 22: 832-836.
20. Mchutchison J, Manns M, Patel K, Poynard T, Lindsay K, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-1069.
21. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
22. Lee S-D, Yu M-L, Cheng P-N, Lai M-Y, Chao Y-C, Hwang S-J, et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 2005; 12: 283-291.
23. Liu C-H, Liu C-J, Lin C-L, Liang C-C, Hsu S-J, Yang S-S, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47: 1260-1269.
24. Yu M-L, Dai C-Y, Huang J-F, Chiu C-F, Yang Y-HC, Hou N-J, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. HEPATOLOGY 2008; 47: 1884-1893.
25. Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47: 1260-1269.
26. Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Hagiwara H, et al. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses. J Viral Hepat 2009; 17: 336-344.
27. Martinot-Peignoux M, Maylin S, Moucari R, Ripault MP, Boyer N, Cardoso AC, et al. Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. Antivir Ther 2009; 14: 501-511.
28. McGovern BH, Nagami EH, Birch CE, Bowen MJ, Reyor LL, Chung RT, et al. Rate of sustained virologic response in relation to baseline hepatitis C virus (HCV) RNA level and rapid virologic clearance in persons with acute HCV infection. J Infect Dis 2009; 200: 877-881.
29. Hsu CS, Liu CH, Liu CJ, Chen CL, Lai MY, Chen PJ, et al. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. Antivir Ther 2009; 14: 45-54.
30. Rumi MG, Aghemo A, D'Ambrosio R, Ronchi G, Del Ninno E, Gallus S, et al. Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study. Antivir Ther 2007; 12: 1033-1040.